Suchergebnisse - "Ritonavir"

PubPharm (2.589)

31

Benefits of nirmatrelvir-ritonavir remain unproven for some populations

enthalten in: CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne | 2022

von McDonald, E. | Lee, T.

CommentOn: CMAJ. 2022 Feb 14;194(6):E218. - PMID 35115376

32

Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir : Prescribers and Patients Beware

enthalten in: Journal of clinical pharmacology | 2022

von Ratain, M. | Greenblatt, D.

33

A literature review of liver function test elevations in rifampin drug-drug interaction studies

enthalten in: Clinical and translational science | 2022

von Ibrahim, S. | Pithavala, Y. | Vourvahis, M. | +1

34

Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia : a pilot study

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Blanco, J. | Rojas, J. | de Lazzari, E. | +10

35

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells : a Dose Escalation Study

enthalten in: Antimicrobial agents and chemotherapy | 2022

von De Nicolò, A. | Calcagno, A. | Motta, I. | +8

36

Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat

enthalten in: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | 2022

von Marin, R. | Streinu-Cercel, A. | Moleriu, L. | +1

37

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

enthalten in: Antiviral research | 2022

von Foo, C. | Abdelnabi, R. | Kaptein, S. | +23

38

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings : ACTG A5288 strategy trial

enthalten in: Journal of the International AIDS Society | 2022

von Avihingsanon, A. | Hughes, M. | Salata, R. | +31

39

Ritonavir-Boosted Exposure of Kinase Inhibitors : an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib

enthalten in: Pharmaceutical research | 2022

von Boosman, R. | de Gooijer, C. | Groenland, S. | +6

40

Investigation of binding characteristics of ritonavir with calf thymus DNA with the help of spectroscopic techniques and molecular simulation

enthalten in: Journal of biomolecular structure & dynamics | 2022

von Kou, S. | Zhou, K. | Lin, Z. | +4